Case Study - Collegium Pharmaceutical’s Approach to Abuse Deterrence Breaks New Ground
Commercial Product Supply
Thursday, March 29, 2018
The opioid abuse epidemic is a serious public health crisis that demands action on the part of many stakeholders. While abuse-deterrent opioids will not solve the opioid abuse epidemic alone, they play a critical role in the fight against it. While Collegium had come up with an innovative new approach to abuse deterrent formulations, it did not have the capacity or resources to manufacture its drug on a commercial scale.
This case study discusses how Collegium Pharmaceutical partnered with Patheon to solve the needed space and expertise necessary to run this unique platform to develop a product that did not fit into the traditional manufacturing mold.
Please complete the short form below to download this case study.